Express Scripts sees no let-up in drug pricing chatter
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall St set to gain on tech rebound, Middle East in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Axsome Therapeutics (AXSM) PT Raised to $380 at Jefferies
Mizuho Securities Remains Sidelined on Express Scripts (ESRX) Following 2017 Guidance
December 14, 2016 1:16 PM ESTMizuho Securities reiterated a Neutral rating and $76.00 price target on Express Scripts (NASDAQ: ESRX) following the company's initial 2017 guidance. 2017 adjusted EPS guidance is $6.82-$7.02, relatively in-line with consensus of $6.93 at the midpoint ($6.92), implies a +7-10% adjusted EPS growth y/y.
Analyst Ann Hynes commented,... More
